Benevolent AI .jpeg

BenevolentAI Limited

Drug Discovery

Membership category
Corporate

4-8 Maple Street, London, W1T 5HD, United Kingdom

BenevolentAI Limited at a glance

BenevolentAI is the global leader in the development and application of artificial intelligence for scientific innovation.

About BenevolentAI Limited

BenevolentAI combines advanced AI and machine learning with cutting edge science to decipher complex disease biology, generate novel insights and discover more effective medicines. Our unique computational R&D platform spans every step of the drug discovery process, powering an in-house pipeline of 25+ drug programmes from early discovery towards clinical phases. With several successful collaborations with leading pharmaceutical organisations, we are also the only AI-drug discovery company with a clinically validated approach, having discovered a leading repurposed drug candidate for COVID-19. BenevolentAI is headquartered in London with a research facility in Cambridge (UK) and a further office in New York, with a team of over 300 world-leading scientists and technologists progressing its mission to reinvent drug discovery and advance life-changing drugs through to the clinic.

Therapeutic area(s)